Transcatheter Versus Surgical Aortic Valve Replacement: Propensity-Matched Comparison.

Published

Journal Article

BACKGROUND: Randomized trials support the use of transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis in high- and intermediate-risk patients, but the generalizability of those results in clinical practice has been challenged. OBJECTIVES: The aim of this study was to determine the safety and effectiveness of TAVR versus surgical aortic valve replacement (SAVR), particularly in intermediate- and high-risk patients, in a nationally representative real-world cohort. METHODS: Using data from the Transcatheter Valve Therapy Registry and Society of Thoracic Surgeons National Database linked to Medicare administrative claims for follow-up, 9,464 propensity-matched intermediate- and high-risk (Society of Thoracic Surgeons Predicted Risk of Mortality score ≥3%) U.S. patients who underwent commercial TAVR or SAVR were examined. Death, stroke, and days alive and out of the hospital to 1 year were compared, as well as discharge home, with subgroup analyses by surgical risk, demographics, and comorbidities. RESULTS: In a propensity-matched cohort (median age 82 years, 48% women, median Society of Thoracic Surgeons Predicted Risk of Mortality score 5.6%), TAVR and SAVR patients experienced no difference in 1-year rates of death (17.3% vs. 17.9%; hazard ratio: 0.93; 95% confidence interval [CI]: 0.83 to 1.04) and stroke (4.2% vs. 3.3%; hazard ratio: 1.18; 95% CI: 0.95 to 1.47), and no difference was observed in the proportion of days alive and out of the hospital to 1 year (rate ratio: 1.00; 95% CI: 0.98 to 1.02). However, TAVR patients were more likely to be discharged home after treatment (69.9% vs. 41.2%; odds ratio: 3.19; 95% CI: 2.84 to 3.58). Results were consistent across most subgroups, including among intermediate- and high-risk patients. CONCLUSIONS: Among unselected intermediate- and high-risk patients, TAVR and SAVR resulted in similar rates of death, stroke, and DAOH to 1 year, but TAVR patients were more likely to be discharged home.

Full Text

Duke Authors

Cited Authors

  • Brennan, JM; Thomas, L; Cohen, DJ; Shahian, D; Wang, A; Mack, MJ; Holmes, DR; Edwards, FH; Frankel, NZ; Baron, SJ; Carroll, J; Thourani, V; Tuzcu, EM; Arnold, SV; Cohn, R; Maser, T; Schawe, B; Strong, S; Stickfort, A; Patrick-Lake, E; Graham, FL; Dai, D; Li, F; Matsouaka, RA; O'Brien, S; Pencina, MJ; Peterson, ED

Published Date

  • July 25, 2017

Published In

Volume / Issue

  • 70 / 4

Start / End Page

  • 439 - 450

PubMed ID

  • 28728688

Pubmed Central ID

  • 28728688

Electronic International Standard Serial Number (EISSN)

  • 1558-3597

Digital Object Identifier (DOI)

  • 10.1016/j.jacc.2017.05.060

Language

  • eng

Conference Location

  • United States